Metastatic Colorectal Cancer Market Forecast to Reach US$ 9,787.5 Million by 2034, Growing at 5.1% CAGR | Fact.MR Report
20. November 2024 07:30 ET
|
FACT.MR
Rockville, MD, Nov. 20, 2024 (GLOBE NEWSWIRE) -- According to Fact.MR, a market research and competitive intelligence provider, the global metastatic colorectal cancer market is estimated to reach a...
Update on Clinical Milestone - CytoMed Therapeutics Announces First Patient Dosed in its First-in-Human Phase I Clinical Trial of Allogeneic CAR-Gamma Delta T Cell Therapy in Patients with Advanced Solid Tumours or Haematological Malignancies
20. November 2024 07:00 ET
|
CYTOMED THERAPEUTICS LIMITED
SINGAPORE, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Further to an announcement on October 7, 2024, CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or “Company”), a Singapore-based biopharmaceutical...
Immunomodulators Market to hit USD 388.7 billion by 2032, says Global Market Insights Inc.
19. November 2024 06:30 ET
|
Global Market Insights Inc.
Selbyville, Delaware, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Immunomodulators Market size was valued at approximately USD 217.7 billion in 2023 and is projected to grow at a CAGR of 6.7% from 2024 to...
Nouscom Completes Patient Enrollment of Randomized Phase 2 Study Evaluating NOUS-209, an Off-the-Shelf Neoantigen Immunotherapy, in dMMR/MSI Metastatic Colorectal Cancer
19. November 2024 02:00 ET
|
Nouscom Srl
Primary efficacy endpoint readout expected in mid-2025Phase 1b studies in dMMR/MSI GI tumors showed that NOUS-209 with pembrolizumab was well-tolerated, generating potent and broad immune responses...
Siren Biotechnology Reveals SRN-101 as Lead Asset for High-Grade Gliomas with Both Orphan Drug and Rare Pediatric Disease Designations from the FDA
18. November 2024 11:00 ET
|
Siren Biotechnology, Inc.
Siren Biotechnology reveals SRN-101 as lead asset for high-grade gliomas with both Orphan Drug and Rare Pediatric Disease Designations from the FDA
Calidi Biotherapeutics Presents Data Supporting RTNova Systemic Technology to Target Metastatic Lung Cancer
18. November 2024 08:00 ET
|
Calidi Biotherapeutics, Inc
SAN DIEGO, Nov. 18, 2024 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted antitumor...
Immatics Announces Third Quarter 2024 Financial Results, Business Update and First Clinical Data on TCER® IMA402 Targeting PRAME
18. November 2024 07:00 ET
|
https://immatics.com/
The Company will now target five major cancer types with its four clinically active compounds across both TCR-T cell therapies and TCR-based Bispecifics Today, Company discloses first clinical...
Calidi Biotherapeutics Announces Closing of $7.5 Million Public Offering of Common Stock
15. November 2024 16:05 ET
|
Calidi Biotherapeutics, Inc
SAN DIEGO, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted antitumor...
Artificial Intelligence Revolutionizing the Future of Oncology: Market Set to Soar to US$8.944 Billion by 2029 | 2024 Research Report
14. November 2024 10:21 ET
|
Research and Markets
Dublin, Nov. 14, 2024 (GLOBE NEWSWIRE) -- The "Artificial Intelligence (AI) in Oncology Market - Forecasts from 2024 to 2029" report has been added to ResearchAndMarkets.com's offering. The...
Calidi Biotherapeutics Announces Pricing of $7.5 Million Public Offering of Common Stock
14. November 2024 08:30 ET
|
Calidi Biotherapeutics, Inc
SAN DIEGO, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE AMERICAN: CLDI) (“Calidi” or the “Company”), a clinical-stage biotechnology company developing a new generation of...